V116 Confers Substantial Protection Against Pneumococcal Disease Among Older Adults, Is More Cost-Effective Than Both PCV20 Alone And PCV15 Combined With PPSV23, Study Finds

Infectious Disease Advisor (1/7, Nye) reports research found that “V116, a 21-valent pneumococcal conjugate vaccine (PCV21), may confer substantial protection against pneumococcal disease among older adults and be more cost-effective than both 20-valent PCV (PCV20) alone and 15-valent PCV (PCV15) combined with the 23-valent pneumococcal polysaccharide vaccine (PPSV23).” The investigators said, “The use of PCV21 by PCV-naïve adults aged ≥65 would markedly reduce the burden of adult pneumococcal disease, making substantial contributions to public health while saving costs in most situations.” The findings were published in Infectious Diseases and Therapy.